Skip to main content
Premium Trial:

Request an Annual Quote

Santaris, Miragen Expand microRNA Partnership to Include Additional Targets


Santaris Pharma and Miragen Therapeutics this week announced that they have expanded their ongoing microRNA therapeutics partnership to include six additional targets.

The companies first began working together in 2010 when they signed a deal giving Miragen access to Santaris' locked nucleic acid technology to develop miRNA inhibitors against four unnamed cardiovascular disease targets (GSN 6/24/2010). As part of the arrangement, Santaris picked up an undisclosed stake in Miragen.

The newest agreement brings the number of targets against which Miragen can apply the LNA technology to ten. As with the first deal, Santaris received an upfront payment of cash and equity, and stands to receive payments based on the achievement of clinical milestones plus royalties on marketed products.

Additional terms were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.